Macitentan slows down the dermal fibrotic process in systemic sclerosis: in vitro findings

C. Corallo, G. Pecetti, M. Iglarz, N. Volpi, D. Franci, A. Montella, R. Nuti, N. Giordano

Article ID: 6007
Vol 27, Issue 2, 2013
DOI: https://doi.org/10.54517/jbrha6007
Received: 9 July 2013; Accepted: 9 July 2013; Available online: 9 July 2013; Issue release: 9 July 2013

Abstract

Systemic sclerosis (or scleroderma) is an autoimmune disease characterized by skin and internal organ fibrosis, caused by microvascular dysfunction. The microvascular damage seems to be a consequence of an endothelial autoimmune response, followed by activation of the inflammatory cascade and massive deposition of collagen. Endothelin-1 (ET-1) contributes to the inflammatory and fibrotic processes by increasing the concentration of pro-inflammatory and pro-fibrotic cytokines, and it is considered one of the most relevant mediators of vascular damage in scleroderma. It is indeed found in very high concentration in serum of sclerodermic patients. Moreover, in these pathological conditions there is an increased expression of ET-1 receptors (ETA and ETB), which mediate the detrimental action of ET-1, and often a change of ETA/ETB ratio. The aim of the present study is to evaluate the in vitro effect of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist, and its major metabolite (ACT-132577) on alpha smooth muscle actin (alphaSMA) expression, evaluated on dermal fibroblasts from healthy subjects and on dermal fibroblasts from lesional and non-lesional skin from sclerodermic patients. The combination of macitentan and its major metabolite reduced the levels of αSMA after 48 h in sclerodermic fibroblasts from lesional skin. No relevant changes in αSMA levels were found in fibroblasts from non-lesional skin, whose behavior is similar to that of dermal fibroblasts from healthy patients.


Keywords

systemic sclerosis;endothelin-1;macitentan;ET receptors


References

Supporting Agencies



Copyright (c) 2013




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).